Appeal 2007-0185
Application 10/305,281
1. A method for reducing LDL cholesterol levels in an mammal which
consists essentially of the administration of 80 mg or 160 mg once per day of
pravastatin, or a pharmaceutically acceptable salt or ester thereof, to a mammal in
need of such treatment.
Grounds of Rejection
1. Claims 1-9 stand rejected under 35 U.S.C. § 103 over Sherwood.
2. Claims 1-9 stand rejected under 35 U.S.C. § 103 over Joshi.
References cited
Joshi US 5,030,447 Jul. 9, 1991
Sherwood GB 2 23 787 Sep. 23, 1992
DISCUSSION
Obviousness - Sherwood
Claims 1-9 stand rejected under 35 U.S.C. § 103 over Sherwood (Answer 4).
The Examiner contends that Sherwood teaches a method of treating
hypercholesterolemia comprising the administration of 1-80 mg of LDL-
cholesterol lowering amounts of HMG-CoA reductase inhibitors, such as
pravastatin, with Chromium (III) in a single or divided dose. (Answer 4.) The
Examiner acknowledges that Sherwood does not expressly teach administering
160 mg of pravastatin, and does not particularly teach a composition containing 80
or 160 mg of pravastatin with chromium (III). (Id.) However, the Examiner
concludes that it would have been obvious to one of ordinary skill in the art to
employ the claimed amount of pravastatin in the method and composition of the
invention because it is optimization of a result effective parameter. (Id.)
- 2 -
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: September 9, 2013